Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. immunehunter

ImmuneHunter SIGNED

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ImmuneHunter project word cloud

Explore the words cloud of the ImmuneHunter project. It provides you a very rough idea of what is the project "ImmuneHunter" about.

tool    profiling    revenues    contracts    ground    analytical    million    data    capacity    establishing    format    vaccines    service    healthy    overview    handle    applies    technologies    2018    unable    scalability    immune    additional    annual    six    applicable    empower    molecular    diagnostics    therapeutics    entry    small    resolution    status    cancer    variation    distinguish    analysed    breaking    premature    throughput    nearly    patient    times    huge    reduce    bioinformatics    figure    healthcare    signed    73    routine    frequent    mva    illness    advantage    competing    sophisticated    capability    mimotope    services    spending    mind    antibody    characterization    contribution    discover    multiplexed    discovered    diseases    25    discovery    analyzing    restricted    chronic    health    demand    detect    platform    accuracy    disease    limited    causes    companies    signatures    grows    simultaneously    biotech    market    superior    ageing    repertoire    amounts    half    clinical    deaths    corresponding    full    unprecedented    death    least    biomarkers    platforms    diagnostic    pilot    radically    diagnose    heart    2020    accurately    tests    ict    protobios   

Project "ImmuneHunter" data sheet

The following table provides information about the project.

Coordinator		 PROTOBIOS OU 

Organization address
address: MAEALUSE 4
city: TALLINN
postcode: 12618
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Estonia [EE]
 Project website http://www.protobios.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2018-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROTOBIOS OU EE (TALLINN) coordinator 50˙000.00

Map

 Project objective

Chronic diseases (cancer, heart and mind diseases) are the leading causes of illness and death. By 2020 their contribution is expected to rise to 73% of all deaths (of which nearly half as premature). To radically reduce the related healthcare spending and contribute to healthy ageing, it is important to diagnose these diseases as early and accurately as possible by analyzing biomarkers. However, the current analytical platforms have been unable to handle the huge amounts of data that need to be analysed for the discovery of new biomarkers, and as a result: (1) only a small number of new biomarkers have been discovered and (2) current routine diagnostic tests are able to provide only a very restricted overview of patient’s health status.

Protobios applies a ground-breaking high-throughput antibody repertoire characterization technology Mimotope Variation Analysis (MVA) to discover new biomarkers, develop novel multiplexed diagnostics, and empower the discovery and development of therapeutics and vaccines. Compared to competing technologies, MVA is superior because (1) it allows to detect and distinguish many different disease signatures simultaneously and (2) the scalability and associated low cost of the MVA process make it applicable for frequent analysis, providing the additional advantage of establishing a robust health assessment tool.

We have used MVA technology to provide clinical diagnostics' development services in a pilot format to a limited number of biotech companies and research institutions. We have witnessed growing demand and signed six-figure contracts for 2018.

The key component of MVA is a sophisticated bioinformatics platform that enables molecular profiling of the immune response at an unprecedented resolution and accuracy. For full-scale market entry, we need to scale up the technical capability of the ICT platform so that the MVA service capacity grows by at least 100 times (corresponding to annual revenues of €20-25 million).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNEHUNTER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNEHUNTER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

JUMPAIR (2018)

Decubitus Ulcers Diseases Diagnoses by means of Smart ICT Anti-Decubitus System based on known Ulcers Activity Biomarkers

Read More  

ClearRing (2018)

An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms.

Read More